Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study

BACKGROUND: Anlotinib is a multitarget tyrosine kinase inhibitor for treating patients with advanced non-small cell lung cancer (NSCLC). We aimed to assess the efficacy and safety of anlotinib in elder patients with advanced NSCLC. METHODS: Elder patients with advanced NSCLC who received anlotinib w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenxian, Shao, Lan, Xu, Yibing, Song, Zhengbo, Lou, Guangyuan, Zhang, Yiping, Chen, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074279/
https://www.ncbi.nlm.nih.gov/pubmed/35524294
http://dx.doi.org/10.1186/s12890-022-01981-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074279/
https://www.ncbi.nlm.nih.gov/pubmed/35524294
http://dx.doi.org/10.1186/s12890-022-01981-5

Ejemplares similares